Calendar

T+3 evidence is mixed rather than decisively bullish: Citi beat the cited Q3 revenue and EPS estimates and raised its return outlook, but the stock fell about 3.4% intraday on October 13 and several post-print targets were cut. Benzinga reported $123.20 trading on October 14, broadly consistent with the packet's $123.21 October 15 anchor; the initial sell-the-news move had not meaningfully reversed. The Goldman note attributed weakness mainly to positioning, while other coverage focused on sequential softness. Social, options-skew, short-interest and employee-score data were unavailable; their zero placeholders above are not measured readings. Sources: https://www.investing.com/news/stock-market-news/why-is-citigroup-stock-sliding-today-93CH-4947285 ; https://www.benzinga.com/analyst-stock-ratings/price-target/26/10/62363435/citigroup-analysts-slash-their-forecasts-following-q3-results ; https://www.tipranks.com/news/the-fly/citi-price-target-lowered-to-155-from-156-at-goldman-sachs-thefly-news

Initial coverage linked the earnings beat to a 2.77% premarket gain, but the packet's October 15 closing anchor is $65.37; the initial reaction should not be assumed to have held. News tone is positive on the beat but mixed on precast and fiscal Q1 segment guidance. No reliable post-print analyst target or estimate revisions were found at this T+1 check; social and options signals were unavailable. [Investing.com reaction](https://uk.investing.com/news/earnings/cmc-shares-rise-3-on-fourth-quarter-earnings-beat-4911845)

Mixed-to-negative immediately after earnings: trusted [AP coverage](https://apnews.com/article/a2edaf9ec297fb75ff2a4e245063ec08) reports a 3.1% October 13 share decline tied to weaker-than-expected revenue despite a profit beat. The October 15 RankAlpha anchor is $82.75, but the packet does not establish whether the initial reaction fully held or reversed. Post-print target cuts are available, though a comprehensive forward-estimate revision series is not. The pre-print $1.85 EPS and $22.15 billion revenue estimates come from a third-party article stored as an earnings document, not an official company release. Social, options, short-interest and employee metrics are unavailable; zero values above are placeholders, not measured readings.

The SEC-filed earnings release confirms stronger Q2 adjusted results and raised guidance, but the market response was mixed: AZZ gained 0.7% on October 14, then fell 5.1% on October 15 to the $130.59 anchor. Four reported post-print analyst target changes include one cut and three increases; broader forward earnings-estimate revisions remain unavailable. The zero-valued social, options, short-interest, employee and news-sentiment fields denote unavailable measurements, not neutral readings. The deterministic prior shifted from positive to neutral, so this T+3 update remains a monitoring view. [#SEC-8K-2026-10-13] [Historical prices](https://chartexchange.com/symbol/nyse-azz/historical/) [Benzinga](https://www.benzinga.com/news/26/10/62385651/azz-analysts-boost-their-forecasts-after-upbeat-q2-results)

The initial October 13 close was $377.76, down 0.2% on the day; shares then closed at $395.62 on October 14 and $406.67 on October 15, about 7.4% above the pre-release October 12 close. The rebound occurred alongside broader healthcare buying, so it should not be attributed solely to earnings. Post-print target revisions were mixed, and a dependable aggregate estimate-revision series is unavailable. Social, options, short-interest and employee readings were not supplied; zero sentiment fields denote unavailable data, not neutral readings. https://chartexchange.com/symbol/nyse-unh/historical/ https://www.benzinga.com/quote/UNH/price-targets

The official earnings release was October 6, although the scheduled follow-up names October 13. Shares fell about 3.8% on October 6, from $45.46 to $43.72, then recovered only partly to the packet's $44.32 October 15 adjusted-close anchor; price action alone does not establish why investors sold. [Historical prices](https://chartexchange.com/symbol/nasdaq-vlgea/historical/) Verified post-print analyst revisions and consensus estimates remain unavailable, so missing coverage is not a positive signal. The prior neutral thesis remains broadly intact, but the Q4 cost pressure and fiscal 2027 investment plan sharpen monitoring priorities.